Email Alert RSS
Volume 11 Issue 6
Nov.  2020
Turn off MathJax
Article Contents
Abstract
References
Related Articles
JIN Fan, XIE Jing, CHEN Rui, WANG Huan-ling. Progress of Remdesivir in the Treatment of Coronavirus Infection[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(6): 659-664. DOI: 10.3969/j.issn.1674-9081.20200034
Citation: JIN Fan, XIE Jing, CHEN Rui, WANG Huan-ling. Progress of Remdesivir in the Treatment of Coronavirus Infection[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(6): 659-664. DOI: 10.3969/j.issn.1674-9081.20200034
shu

Progress of Remdesivir in the Treatment of Coronavirus Infection

  • 1.

    Department of Infection Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author:

    WANG Huan-ling  Tel: 86-10-69158360, E-mail: wanghuanling@pumch.cn

  • Received Date: February 16, 2020
  • Accepted Date: February 22, 2020
  • Available Online: February 27, 2020
  • Issue Publish Date: November 29, 2020
    Graphical Abstract
    • Abstract
  • In December 2019, the outbreak of coronavirus disease 2019(COVID-19)occurred in Wuhan, China. It became the third outbreak of coronavirus infection after severe acute respiratory syndrome(SARS)and Middle East respiratory syndrome(MERS)in the past decade. COVID-19 is caused by 2019-novel coronavirus(2019-nCoV)infection that has spread rapidly and extensively.2019-nCoV is highly contagious, but there is no specific antiviral drug for coronavirus at present. Remdesivir, a nucleoside analogue, showed anti-SARS-CoV and anti-MERS-CoV activities in vitro and in animal models, and showed no obvious adverse reaction in the multicenter, randomized, controlled clinical trial of Ebola virus infection. Remdesivir is considered to be the great promising drug for treating 2019-nCoV infection. This article reviewed the research history and potential clinical applications of remdesivir in the treatment of coronavirus infection.
    • FullText(HTML)
    • References (25)
  • [1]
    van Boheemen S, de Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans[J]. mBio, 2012, 3:e00473-e00412.
    [2]
    Lu H, Stratton CW, Tang YW. Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle[J]. J Med Virol, 2020, 92:401-402.
    [3]
    Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States[J]. N Engl J Med, 2020, 382:929-936.
    [4]
    Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses[J]. Sci Transl Med, 2017, 9:eaal3653.
    [5]
    Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral remdesivir(GS-5734)Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease[J]. mBio, 2018, 9:e00221-e00218.
    [6]
    Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV[J]. Nat Commun, 2020, 11:222.
    [7]
    World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 [EB/OL]. http://www.who.int/csr/sars/country/table2004_04_21/en/.
    [8]
    World Health Organization. MERS situation update 2019[EB/OL]. http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.
    [9]
    Chen L, Liu W, Zhang Q, et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak[J]. Emerg Microbes Infect, 2020, 9:313-319.
    [10]
    Woo PC, Lau SK, Huang Y, et al. Coronavirus diversity, phylogeny and interspecies jumping[J]. Exp Biol Med(Maywood), 2009, 234:1117-1127.
    [11]
    Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus[J]. Microbiol Mol Biol Rev, 2005, 69:635.
    [12]
    Bonavia A, Zelus BD, Wentworth DE, et al. Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E[J]. J Virol, 2003, 77:2530-2538.
    [13]
    Zumla A, Chan JF, Azhar EI, et al. Coronaviruses-drug discovery and therapeutic options[J]. Nat Rev Drug Discov, 2016, 15:327-347.
    [14]
    Chu CK, Gadthula S, Chen X, et al. Antiviral activity of nucleoside analogues against SARS-coronavirus(SARS-coV)[J]. Antivir Chem Chemother, 2006, 17:285-289.
    [15]
    Cho A, Saunders OL, Butler T, et al. Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7, 9-dideazaadenosine C-nucleosides[J]. Bioorg Med Chem Lett, 2012, 22, 2705-2707.
    [16]
    de Wilde AH, Snijder EJ, Kikkert M, et al. Host Factors in Coronavirus Replication[J]. Curr Top Microbiol Immunol, 2018, 419:1-42.
    [17]
    Sims AC, Baric RS, Yount B, et al. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia:role of ciliated cells in viral spread in the conducting airways of the lungs[J]. J Virol, 2005, 79:15511-15524.
    [18]
    Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro[J]. Cell Res, 2020, 130:269-271.
    [19]
    World Health Organization. Summaries of evidence from selected experimental therapeutics[EB/OL]. https://www.who.int/ebola/drc-2018/treatments-approved-for-compassi-onate-use-update/en/.
    [20]
    Mulangu S, Dodd LE, Davey RT, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics[J]. N Engl J Med, 2019, 381:2293-2303.
    [21]
    Chan JFW, Yuan SF, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission:a study of a family cluster[J]. Lancet, 2020, 395:514-523.
    [22]
    Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395:497-506.
    [23]
    Clinical Trials. Severe 2019-nCoV Remdesivir RCT[EB/OL]. https://clinicaltrials.gov/ct2/show/NCT04257656?term=remdesivir&draw=2&rank=1.
    [24]
    Clinical Trials. Mild/Moderate 2019-nCoV Remdesivir RCT[EB/OL]. https://clinicaltrials.gov/ct2/show/NCT04252664?term=remdesivir&draw=2&rank=2.
    [25]
    Clinical Trials. Adaptive COVID-19 Treatment Trial[EB/OL]. https://clinicaltrials.gov/ct2/show/NCT04280705?cond=Adaptive+COVID-19+Treatment+Trial&draw=2&rank=1.
    • Related Articles

  • Related Articles

    [1]LIU Shupeng, YU Mengyang, WU Xiaofei, WANG Hongyun. Clinical Landscape of Therapeutic Cancer Vaccines: Challenges and Opportunities[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(6): 1356-1363. DOI: 10.12290/xhyxzz.2024-0130
    [2]LI Jianfeng, ZHANG Jingyi, LI Likang, LIU Yingxin, LI Guowei. Approach to Handling Missing Data in Clinical Trials[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1165-1172. DOI: 10.12290/xhyxzz.2023-0415
    [3]REN Yiming, LI Rui, TANG Si, JI Guanghe, QIN Zelin, ZHAO Leying, TONG Jiaxi, CHEN Yuxuan, GAO Jiaqi, YU Mingkun, RONG Hongguo, XIA Ruyu, FEI Yutong. Public's Knowledge and Experiences Towards Pediatric Clinical Trials: Methodological Characteristics Analysis[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 1076-1083. DOI: 10.12290/xhyxzz.2022-0620
    [4]CHEN Chen, HAN Xiaohong. Clinical Trials of Rare Diseases in China over One Decade: Based on the Chinese First List of Rare Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1028-1035. DOI: 10.12290/xhyxzz.2022-0010
    [5]CHEN Zihan, LI Naishi, LIAN Xiaolan. Coronavirus Disease 2019 and Thyroid Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 487-492. DOI: 10.12290/xhyxzz.2021-0791
    [6]ZHOU Jingya, FAN Junping, ZHANG Meng, ZHOU Jiong. Classification and Coding for Coronavirus Disease 2019 by International Classification ofDiseases: Updates and Interpretation[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 328-332. DOI: 10.12290/xhyxzz.2021-0236
    [7]DUAN Yan-ping, CAO Jin-ya, WEI Jing, JIANG Jing, ZHAO Xiao-hui, GENG Wen-qi, ZHU Hua-dong. Basic Needs of the First Batch of Medical Staff in the Fever Clinic of Peking Union Medical College Hospital during Coronavirus Disease 2019 Outbreak: A Qualitative Study[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 54-58. DOI: 10.3969/j.issn.1674-9081.2021.01.001
    [8]WANG Shi-rui, CHEN Shi, ZHU Hui-juan. Evaluation and Treatment of Coronavirus Disease 2019 with Obesity[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 13-17. DOI: 10.12290/xhyxzz.20200244
    [9]SUN Xian-song, HOU Xiao-rong, LIU Xiao-ming, ZHOU Bing, CHAI Shuang, HU Ke, QIU Jie, ZHANG Fu-quan. The Experience and Inspiration on the Prevention and Control of Coronavirus Disease 2019 in the Department of Radiotherapy[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 9-12. DOI: 10.12290/xhyxzz.20200242
    [10]PENG Min, SUN Xue-feng, ZHAO Jing, WANG Jing-lan, SONG Lan, WANG Meng-zhao, SHI Ju-hong, LI Tai-sheng, ZHANG Feng-chun, CAI Bai-qiang, ZHU Yuan-jue. Differential Diagnosis between Coronavirus Disease 2019 and Interstitial Pneumonia[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(6): 654-658. DOI: 10.3969/j.issn.1674-9081.2020.06.001

  • Cited by

    Periodical cited type(5)

    1. 王敏，胡兆，徐晓巍，郑思，李姣，姚焰. 融合知识驱动和数据驱动的混合决策模型构建：以室性心动过速病因诊断为例. 协和医学杂志. 2025(02): 454-461 . 本站查看
    2. 吴孟达，毛紫阳，王丹. Shapley值及其应用. 数学建模及其应用. 2024(01): 110-119 .
    3. 李深，唐霁松，曹颖，刘琳，谭魁，万毅，卿竹君，景渝，谢明莉，彭正良. XGBoost模型分析院内心脏骤停患者恢复自主循环的特征. 临床急诊杂志. 2024(11): 579-585 .
    4. 胡冬雪，牛承志，赵春雨，赵丽丽，王鑫. 基于机器学习的ICU多发伤患者发生谵妄预测模型的构建与评估. 中华创伤杂志. 2024(11): 1016-1021 .
    5. 张伟丽，邱晨，宋玉祥，罗云根，宋咪，高远. 机器学习在谵妄风险预测模型构建中的研究进展. 解放军医学院学报. 2023(11): 1292-1296 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (331) PDF downloads (30) Cited by(7)
    Related
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

      Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return
      x Close Forever Close